0 results available. Select is focused ,type to refine list, press Down to open the menu,
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The ...
The following section summarizes insights on Vaccinex Inc's EV / Free Cash Flow:
We've identified the following companies as similar to Vaccinex Inc because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to EV / Free Cash Flow in the valuation category include:
Measures the dollars in Enterprise Value for each dollar of free cash flow over the last twelve months.
Enterprise Value / Free Cash Flow measures the dollars in Enterprise Value for each dollar of unlevered free cash flow earned over the last 12 months.
TEV / UFCF = Total Enterprise Value / Unlevered Free Cash Flow
Applying this formula, Vaccinex’s EV/FCF is calculated below:
Total Enterprise Value [ $201.753 T ]
(/) Unlevered Free Cash Flow [ -$17.183 M ]
(=) TEV / UFCF [ 0.0x ]
The tables below summarizes the trend in Vaccinex’s EV/FCF over the last five years:
| Date | Enterprise Value | Unlevered Free Cash Flow | TEV / UFCF |
|---|---|---|---|
| 2019-12-31 | $82.053 M | -$26.704 M | −3.1 |
| 2020-12-31 | $63.818 M | -$25.576 M | −2.5 |
| 2021-12-31 | $18.581 M | -$22.395 M | −0.8 |
| 2022-12-31 | $24.819 M | -$17.024 M | −1.5 |
| 2023-12-31 | $8.675 M | -$16.96 M | −0.5 |
Read more about total enterprise value (tev) and unlevered free cash flow